evolcSign inStart free
Menu

Open call for tenders

Furnizare medicamente citostatice

Antineoplastic agents · for Institutul de Pneumoftiziologie "Marius Nasta" · Romania · published in Romanian

What the buyer wants

Autoritatea contractanta urmareaste achizitionarea de Medicamente oncologice, prin aplicarea unei proceduri de licitatie deschisa in urma careia se va incheia un acord cadru pe 24 de luni cu ocupantii primelor trei locuri declarati castigatori. Autoritatea contractanta va raspunde in mod clar si complet tuturor solicitarilor de clarificari in a 11-a zi inainte de data limita stabilita pentru depunerea ofertelor, in masura in care sunt transmise in termenul precizat. Numărul de zile până la care se pot solicita claricări înainte de data limita de depunere a ofertelor/candidaturilor: 18 zile.

30 lots

  1. NIVOLUMABUM fl.10 mg/mL;
  2. PEMBROLIZUMABUM fl. 25 mg/mL;
  3. AMIVANTAMABUM fl. 350 mg/7 mL
  4. ATEZOLIZUMABUM fl. 1200 mg/20 mL
  5. RAMUCIRUMABUM fl. 10 mg/mL;
  6. CEMIPLIMABUM fl. 50 mg/mL;
  7. DURVALUMABUM fl. 50 mg/mL;
  8. CARBOPLATINUM fl. 10 mg/mL;
  9. PACLITAXELUM fl. 6 mg/mL; 30 mg/5 mL
  10. PACLITAXELUM fl. 6 mg/mL; 100 mg/16,7 mL
  11. CISPLATINUM fl 1 mg/mL; 10 mg/10 mL
  12. CISPLATINUM fl 1 mg/mL; 25 mg/25 mL
  13. CISPLATINUM fl 1 mg/mL; 50 mg/50 mL
  14. CISPLATINUM fl 1 mg/mL; 100 mg/100 mL
  15. PEMETREXEDUM 100 mg/flacon
  16. PEMETREXEDUM 500 mg/flacon
  17. PEMETREXEDUM 850 mg/flacon
  18. PEMETREXEDUM 1000 mg/flacon
  19. VINORELBINUM 10 mg/mL; 10 mg/1 mL
  20. VINORELBINUM 10 mg/mL; mg/mL; 50 mg/5 mL
  21. ETOPOSIDUM fl.20 mg/mL; 100 mg/5 mL
  22. ETOPOSIDUM fl. 20 mg/mL; 200 mg/10 mL
  23. DOCETAXELUM fl. 20 mg/mL; 20 mg/1 mL
  24. DOCETAXELUM fl. 20 mg/mL; 80 mg/4 mL
  25. DOCETAXELUM fl. 20 mg/mL; 120 mg/6 mL
  26. DOCETAXELUM fl. 20 mg/mL; 140 mg/7 mL
  27. DOCETAXELUM fl. 20 mg/mL; 160 mg/8 mL
  28. PACLITAXELUM fl. 100 mg/flacon
  29. TOPOTECANUM fl. 1 mg/2 mL
  30. TOPOTECANUM fl. 4 mg/5 mL

Companies that won similar tenders

Companies that won public tenders in the same category (Antineoplastic agents) since 2024, according to EU award notices. Likely competitors, or partners for a joint offer.